Patents Examined by Karen A. Canella
  • Patent number: 10782300
    Abstract: The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including monitoring a concentration of free GPC3 in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be further administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: September 22, 2020
    Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, F. Hoffmann-La Roche AG
    Inventors: Toshihiko Ohtomo, Ya-Chi Chen, Jun Amano, Mikiko Nakamura
  • Patent number: 10780096
    Abstract: The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 22, 2020
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
    Inventors: Patricius Henrikus Cornelis Van Berkel, Philip Wilson Howard, John Hartley
  • Patent number: 10751430
    Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: August 25, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jamey Weichert, Paul Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz, Peter Carlson
  • Patent number: 10745481
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: August 18, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • Patent number: 10736940
    Abstract: Combined preparations for the treatment of cancer are described. The combined preparations comprise: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) an anti-neoplastic agent, wherein the anti-neoplastic agent is a platinum-based anti-neoplastic agent or a topoisomerase I inhibitor. Methods for the treatment of cancer using the combined preparations are also described.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: August 11, 2020
    Assignee: IMMUTEP S.A.S.
    Inventor: Frederic Triebel
  • Patent number: 10736949
    Abstract: A method of treating a malignant solid tumor in a subject is disclosed herein. The method includes the steps of administering to the subject an immunomodulatory dose of a radiohalogenated compound that is differentially taken up by and retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by intratumorally injecting into (or treating via a separate method) at least one of the malignant solid tumors a composition that includes one or more agents capable of stimulating specific immune cells within the tumor microenvironment. In certain exemplary embodiments, the radiohalogenated compound has the formula: wherein R1 is a radioactive halogen isotope, n is 18 and R2 is —N+(CH3)3.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: August 11, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jamey Weichert, Paul M. Sondel, Anatoly Pinchuk, Zachary Morris, Mario Otto, Bryan Bednarz
  • Patent number: 10738094
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 11, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10729738
    Abstract: The invention relates generally to disulfide drug conjugates wherein a linker comprising a sulfur-bearing carbon atom substituted with at least one hydrocarbyl or substituted hydrocarbyl is conjugated by a disulfide bond to a cysteine sulfur atom of a targeting carrier, and wherein the linker is further conjugated to a drug moiety. The invention further relates to activated linker-drug conjugates suitable for conjugation to a targeting carrier by a disulfide bond. The invention further relates to methods for preparing hindered disulfide drug conjugates.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: August 4, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Zhonghua Pei, Thomas Pillow, Jack Sadowsky, Jinhua Chen, John Wai
  • Patent number: 10729768
    Abstract: Highly effective combinations of a compound of formula A (a PI3K? selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K? and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: August 4, 2020
    Assignees: TG Therapeutics, Inc., Rhizen Pharmaceuticals SA, Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Michael S. Weiss, Hari P. Miskin, Peter Sportelli, Swaroop K. V. S. Vakkalanka
  • Patent number: 10695400
    Abstract: The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions described are useful for the treatment of certain cancers, including, e.g., breast cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, as well as others. In addition, the description provides a delivery system for the controlled release of at least one of ETBR antagonists, caspase-8 inhibitors or a combination thereof, optionally including at least one of an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide, or a combination thereof, to the central nervous system that are useful for treating cancers that have spread to the brain.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: June 30, 2020
    Assignee: ENB THERAPEUTICS, INC.
    Inventor: Sumayah Jamal
  • Patent number: 10695396
    Abstract: The present invention provides a peptide comprising the amino acid sequence of any of the formulas (I)-(III) below: (I) an amino acid sequence of (X1)[D]P[D](X2)[D] wherein X1 is W or F, X2 is S or T, and each amino acid symbol immediately followed by symbol [D] is a D form of the amino acid, (II) an amino acid sequence of P[D]T[D](X)n F[D] wherein (X)n is any amino acid in the number of n selected independently of each other, n is an integer of 0-4, and the symbol [D] is as defined above, (III) an amino acid sequence that is a Retro-inverso of the amino acid sequence of any of the aforementioned (I) and the aforementioned (II); and a conjugate containing the peptide and a functional part.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: June 30, 2020
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Michiko Fukuda, Motohiro Nonaka
  • Patent number: 10688181
    Abstract: There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: June 23, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas J. Kipps, Liguang Chen, Bing Cui
  • Patent number: 10677688
    Abstract: Various medical systems and methods are described, including a medical monitoring system. The medical monitoring system can have a fluid system configured to receive bodily fluid and optically analyze said fluid to determine analyte concentration. The fluid system can have a removable portion. The removable portion can have an opening with a port. The system can also have a container configured to contain anticoagulant. The container can have a portion configured to mate with the port of the removable portion. The container can be further configured to not fit into a conventional luer fitting. An anti-coagulant insertion apparatus is also described. The apparatus can have a syringe, a dock with a port, and an adapter configured to connect the syringe to the port. The dock can also have a tab configured to move with the port.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: June 9, 2020
    Assignee: OptiScan Biomedical Corporation
    Inventors: Gil Rivas, Michael Butler, Jeffrey T. Chiou, Eugene Lim
  • Patent number: 10676773
    Abstract: An antibody has at a heavy chain thereof a C-terminal extension that includes at least one glutamine that is a substrate for transglutaminase, enabling the transglutaminase-mediated preparation antibody-drug conjugates using such antibody.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: June 9, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chetana Rao-Naik, Shrikant Deshpande
  • Patent number: 10670601
    Abstract: This document provides methods and materials related to treating renal cell carcinoma. For example, methods and materials for assessing a cancer patient (e.g., a renal cell carcinoma patient) for tumor or peritumoral tissue containing CD14+ cells and proceeding with a cancer treatment option (e.g., a renal cell carcinoma treatment option) based on the presence, absence, or level of CD14+ cells present within the tumor or peritumoral tissue are provided.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: June 2, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Allan B. Dietz
  • Patent number: 10669338
    Abstract: The present invention concerns compositions and methods of use of anti-PD-1 antibodies comprising CDR sequences corresponding to SEQ ID NO:1 to SEQ ID NO:6. Preferably the antibody is a humanized antibody comprising the variable region amino acid sequences of SEQ ID NO: 9 and SEQ ID NO:10. The antibodies are of use to treat cancer and may be administered alone or with another standard anti-cancer therapy. The methods may comprise administering the anti-PD-1 antibody or antigen-binding fragment thereof in combination with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-?), and/or other checkpoint inhibitor antibodies.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 2, 2020
    Assignee: Immunomedics, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg
  • Patent number: 10662252
    Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-?), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: May 26, 2020
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi, Diane Rossi
  • Patent number: 10653667
    Abstract: The present invention provides an agent for prophylactic treatment, therapeutic treatment, or prevention of metastasis of giant cell tumor occurring in a bone and soft tissue, chondrosarcoma, or bone sarcoma, a local infusion for artery embolization, and an artificial bone, which comprises a substance having a PPAR?-agonistic activity and/or a PPAR? expression-inducing activity as an active ingredient. The agent for prophylactic treatment, therapeutic treatment, or prevention of metastasis, the local infusion for artery embolization, and the artificial bone of the present invention are a radical therapeutic agent or radical therapeutic material that can cause apoptosis in giant cell tumor occurring in a bone and soft tissue, chondrosarcoma, or bone sarcoma to make the tumor disappear, and can induce differentiation of the tumor into fat cells to make the tumor disappear.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: May 19, 2020
    Assignee: NIPPON CHEMIPHAR CO., LTD
    Inventors: Akihiko Takeuchi, Hiroyuki Tsuchiya
  • Patent number: 10640561
    Abstract: Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, acute leukemia cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: May 5, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • Patent number: 10618948
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: April 14, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh